Skip Nav Destination
Issues
1 March 2013
-
Cover Image
Cover Image
The anticancer activity of green tea catechins has been known for a long time, but the mechanism of action is still unclear. The cover figure shows terminal differentiation of cancer-induced myeloid cells in the presence of the green tea catechin formulation Polyphenon E. The differentiation of immunosuppressive myeloid cells by green tea catechins promotes an antitumor T-cell response in neuroblastoma. For details, see the article by Santilli and colleagues on page 1116 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
CCR Translations
CCR New Strategies
Statistics in Clinical Cancer Research
Molecular Pathways
Review
CCR Focus
Human Cancer Biology
Lack of Estrogen Receptor-α Is Associated with Epithelial–Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma
Elisabeth Wik; Maria B. Ræder; Camilla Krakstad; Jone Trovik; Even Birkeland; Erling A. Hoivik; Siv Mjos; Henrica M.J. Werner; Monica Mannelqvist; Ingunn M. Stefansson; Anne M. Oyan; Karl H. Kalland; Lars A. Akslen; Helga B. Salvesen
Cancer Therapy: Preclinical
Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells
Giorgia Santilli; Izabela Piotrowska; Sandra Cantilena; Olesya Chayka; Marco D'Alicarnasso; Daniel A. Morgenstern; Nourredine Himoudi; Katie Pearson; John Anderson; Adrian J. Thrasher; Arturo Sala
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
Christian A. Gerdes; Valeria Gonzalez Nicolini; Sylvia Herter; Erwin van Puijenbroek; Sabine Lang; Michaela Roemmele; Ekkehard Moessner; Olivier Freytag; Thomas Friess; Carola H. Ries; Birgit Bossenmaier; Hans Joachim Mueller; Pablo Umaña
Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Hirohiko Kamiyama; Sherri Rauenzahn; Joong Sup Shim; Collins A. Karikari; Georg Feldmann; Li Hua; Mihoko Kamiyama; F. William Schuler; Ming-Tseh Lin; Robert M. Beaty; Balasubramanyam Karanam; Hong Liang; Michael E. Mullendore; Guanglan Mo; Manuel Hidalgo; Elizabeth Jaffee; Ralph H. Hruban; H.A. Jinnah; Richard B.S. Roden; Antonio Jimeno; Jun O. Liu; Anirban Maitra; James R. Eshleman
Inactivation or Loss of TTP Promotes Invasion in Head and Neck Cancer via Transcript Stabilization and Secretion of MMP9, MMP2, and IL-6
Elizabeth A. Van Tubergen; Rajat Banerjee; Min Liu; Robert Vander Broek; Emily Light; Shiuhyang Kuo; Stephen E. Feinberg; Amanda L. Willis; Gregory Wolf; Thomas Carey; Carol Bradford; Mark Prince; Francis P. Worden; Keith L. Kirkwood; Nisha J. D'Silva
Imaging, Diagnosis, Prognosis
Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
Antoine Italiano; Pauline Lagarde; Céline Brulard; Philippe Terrier; Marick Laë; Bernard Marques; Dominique Ranchere-Vince; Jean-Jacques Michels; Martine Trassard; Angela Cioffi; Sophie Piperno-Neumann; Christine Chevreau; Jean-Yves Blay; Corinne Delcambre; Nicolas Isambert; Nicolas Penel; Jacques-Olivier Bay; Sylvie Bonvalot; Axel Le Cesne; Jean-Michel Coindre; Frédéric Chibon
Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer
Swati Suryawanshi; Anda M. Vlad; Hui-Min Lin; Gina Mantia-Smaldone; Robin Laskey; MinJae Lee; Yan Lin; Nicole Donnellan; Marcia Klein-Patel; Ted Lee; Suketu Mansuria; Esther Elishaev; Raluca Budiu; Robert P. Edwards; Xin Huang
Cancer Therapy: Clinical
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick; Adriano Piris; Alexandria P. Cogdill; Zachary A. Cooper; Cecilia Lezcano; Cristina R. Ferrone; Devarati Mitra; Andrea Boni; Lindsay P. Newton; Chengwen Liu; Weiyi Peng; Ryan J. Sullivan; Donald P. Lawrence; F. Stephen Hodi; Willem W. Overwijk; Gregory Lizée; George F. Murphy; Patrick Hwu; Keith T. Flaherty; David E. Fisher; Jennifer A. Wargo
Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
Colin D. Weekes; Daniel D. Von Hoff; Alex A. Adjei; Diane P. Leffingwell; S. Gail Eckhardt; Lia Gore; Karl D. Lewis; Glen J. Weiss; Ramesh K. Ramanathan; Grace K. Dy; Wen W. Ma; Beth Sheedy; Cory Iverson; Jeffrey N. Miner; Zancong Shen; Li-Tain Yeh; Ronald L. Dubowy; Michael Jeffers; Prabhu Rajagopalan; Neil J. Clendeninn
Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies
Dong M. Shin; Hongzheng Zhang; Nabil F. Saba; Amy Y. Chen; Sreenivas Nannapaneni; A.R.M. Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C. Brandes; William J. Grist; Rachel Moreno-Williams; Jonathan J. Beitler; Sufi M. Thomas; Zhengjia Chen; Hyung Ju C. Shin; Jennifer R. Grandis; Fadlo R. Khuri; Zhuo Georgia Chen
Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Eric Angevin; Jose A. Lopez-Martin; Chia-Chi Lin; Jürgen E. Gschwend; Andrea Harzstark; Daniel Castellano; Jean-Charles Soria; Paramita Sen; Julie Chang; Michael Shi; Andrea Kay; Bernard Escudier
Predictive Biomarkers and Personalized Medicine
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
Bryan P. Schneider; Robert J. Gray; Milan Radovich; Fei Shen; Gail Vance; Lang Li; Guanglong Jiang; Kathy D. Miller; Julie R. Gralow; Maura N. Dickler; Melody A. Cobleigh; Edith A. Perez; Tamara N. Shenkier; Kirsten Vang Nielsen; Sven Müller; Ann Thor; George W. Sledge, Jr; Joseph A. Sparano; Nancy E. Davidson; Sunil S. Badve
Letters to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds